Expand DNTH Menu
DNTH MENU

DNTH Latest Press Releases

-- May 19, 2026 --

Oorja Bio Launches as a Clinical-Stage Company to Develop Groundbreaking Therapies for Idiopathic Pulmonary Fibrosis (IPF) and Other Fibrotic Diseases Globe Newswire 3:00 PM

-- May 5, 2026 --

LBL-047 Prioritized for Clinical Development in Sjgren's Disease, Systemic Lupus Erythematosus, and Dermatomyositis Globe Newswire 10:57 PM
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 2026 Financial Results Globe Newswire 4:01 PM

-- May 1, 2026 --

Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:30 PM

-- April 6, 2026 --

Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:01 PM

-- March 12, 2026 --

Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares Globe Newswire 4:01 PM

-- March 10, 2026 --

Dianthus Therapeutics, Inc. Announces Pricing of Upsized $625 Million Underwritten Public Offering Globe Newswire 10:54 PM

-- March 9, 2026 --

Dianthus Therapeutics, Inc. Announces Proposed $400 Million Underwritten Public Offering Globe Newswire 4:01 PM
Dianthus Therapeutics Highlights Recent Business Achievements, Including GO Decision for Phase 3 CAPTIVATE CIDP Trial, and Reports Q4 and FY 2025 Financial Results Globe Newswire 7:09 AM
Dianthus Therapeutics Announces Early GO Decision Following Interim Responder Analysis in Phase 3 CAPTIVATE Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Globe Newswire 7:00 AM

-- March 8, 2026 --

Dianthus Therapeutics to Host Conference Call and Webcast to Discuss the Interim Responder Analysis Results of the Phase 3 Captivate Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Globe Newswire 5:00 PM

-- March 3, 2026 --

Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:01 PM

-- February 24, 2026 --

Dianthus Therapeutics to Participate in The TD Cowen 46th Annual Health Care Conference Globe Newswire 7:00 AM

-- February 5, 2026 --

Dianthus Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 Globe Newswire 7:00 AM

-- January 5, 2026 --

Dianthus Therapeutics To Participate in the 44th Annual J.P. Morgan Healthcare Conference Globe Newswire 7:00 AM
Market Data Delayed 15 Minutes